Tuesday, 3 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Lupin Product Launch

Lupin launched generic Raltegravir Tablets 600 mg in the United States. It is first-to-file, with 180-day exclusivity.

Source

NSE filing, NSE: LUPIN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Lupin Ltd: key numbers

Share price
₹2,015.90
Market cap
₹92,186 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
16.7×Sector 47.2×
Promoter holding
46.84%-0.01% QoQ
FII holding
23.28%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
18:04 IST BSE
Regulatory Approval

Lupin Regulatory Approval

Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.

Other product launch announcements

All →